PIK-75 is primarily used in biochemical and pharmaceutical research as a selective inhibitor of the PI3K (phosphoinositide 3-kinase) signaling pathway, specifically targeting the p110α isoform. This compound is valuable in studying cellular processes such as proliferation, survival, and metabolism, which are often dysregulated in cancer. Due to its ability to suppress PI3K activity, PIK-75 has been employed in preclinical studies to investigate tumor growth inhibition in various cancer models, including breast, lung, and leukemia. It also serves as a tool compound for validating PI3K as a therapeutic target and for understanding resistance mechanisms to other kinase inhibitors. Its use is largely confined to laboratory research due to stability and toxicity limitations in vivo.